#immunization

Vaccine

The cold chain in vaccination refers to:

Cold chain in vaccination encompasses system ensuring vaccines maintained within manufacturer recommended temperature range during storage and transport from production facility through national, regional, district stores to health centers and outreach vaccination sessions preserving potency until moment administration. Term refers to low temperature preservation, not manufacturing or injection method. Typical vaccines requiring 2 to 8C refrigeration include DTP, hepatitis B, pentavalent, IPV, BCG; some lyophilized vaccines stable at ambient during transport but reconstituted require immediate use; ultracold chain minus 60 to 80C required for Pfizer BioNTech mRNA and minus 20C Moderna needing specialized freezers, dry ice shippers. Infrastructure comprises walk-in cold rooms with standby generators, ice-lined refrigerators maintaining holdover 16 hours without electricity, refrigerated trucks with data loggers recording temperature every 5 minutes, cold boxes with conditioned ice packs frozen at minus 20 then conditioned to 0C preventing freezing aluminum adjuvanted vaccines, vaccine carriers with foam insulation for daily outreach preserving temperature 24 hours. Continuous monitoring via 30 day electronic loggers, vaccine vial monitors VVM chemical labels indicating cumulative heat exposure via color change, freeze indicators for freeze sensitive vaccines, and standard operating procedures handling stock management ensure potency. Breaks cause costly wastage and vaccine failure undermining trust.

Ref: WHO Cold chain storage transport low temperature 2-8C; WHO PQS devices catalog; CDC storage.

View Details

Vaccine

A limitation of polysaccharide vaccines is that they:

Polysaccharide vaccines face intrinsic limitation that they induce serotype specific immunity due to structural diversity of capsular polysaccharides among bacterial strains. For instance Streptococcus pneumoniae possesses greater than 90 serotypes each with distinct repeating unit composition differences in sugar sequence, glycosidic linkage alpha 1-3 vs beta 1-4, side chains and O-acetylation patterns dictating distinct antigenic epitopes. Antib Antibodies raised against polysaccharide of serotype 14 recognizing beta-D-galactose 1-4 linkage do not cross react with serotype 19F containing glucose rhamnose, providing no protection against heterologous type. Consequently pneumococcal polysaccharide vaccine PPSV23 covers 23 most prevalent serotypes but still leaves coverage gap and replacement by non vaccine serotypes observed post introduction due to ecological niche filling. Similarly meningococcal polysaccharide A,C,W,Y required separately, Haemophilus type b polysaccharide PRP not cross reacting with other H. influenzae types. T-independent nature compounds limitation producing IgM and IgG2 without memory, ineffective in infants. Conjugate technology partially overcomes but serotype coverage still finite, necessitating continual surveillance to update formulation based on serotype epidemiology and antimicrobial resistance patterns.

Ref: Geno Immun Rev Polysaccharide serotype specific; Plotkin Pneumococcal limitation serotype; WHO.

View Details

Vaccine

Diphtheria and tetanus vaccines are examples of:

Diphtheria and tetanus vaccines belong to toxoid class defined by formalin inactivated exotoxins maintaining immunogenicity while lacking toxicity. Diphtheria vaccine contains diphtheria toxoid derived from Corynebacterium diphtheriae Park-Williams 8 strain carrying corynebacteriophage tox gene encoding ADP-ribosyltransferase secreted into culture medium purified then detoxified. Tetanus vaccine uses tetanus toxoid from Clostridium tetani Harvard strain fermenter grown anaerobically producing tetanospasmin. Both toxoids formulated with aluminum phosphate or hydroxide adjuvant as DT, Td, DTP combos. Protection mediated not by antibacterial immunity but antitoxic antibodies binding toxin in extracellular fluid preventing entry into target cells: diphtheria antitoxin prevents binding heart muscle and nerves, tetanus antitoxin prevents attachment at neuromuscular junction. Antibody titer greater than 0.01 IU per mL provides minimal protection, 0.1 IU full. Vaccinated individuals may still colonize with Corynebacterium but do not develop systemic intoxication. Herd immunity reduces toxin circulation. Booster every ten years recommended for tetanus because environmental spores ubiquitous in soil. Discovery by Behring antitoxin serum therapy preceded toxoid use.

Ref: WHO Tetanus Diphtheria toxoid vaccines; Plotkin Toxoid category; Rappuoli.

View Details

Vaccine

Which chemical is commonly used to inactivate toxins in toxoid vaccines?

Toxoid vaccines prevent disease caused by potent bacterial exotoxins rather than bacterial invasion itself. Diphtheria toxin 58 kDa AB toxin ADP-ribosylates elongation factor eEF2 halting protein synthesis causing myocardial necrosis, neuritis; tetanus toxin tetanospasmin 150 kDa metalloprotease cleaves VAMP synaptobrevin preventing inhibitory neurotransmitter release causing spastic paralysis. Native toxins lethal at nanogram per kg doses far too dangerous for direct use. Formaldehyde formalin approximately 37 percent formaldehyde aqueous solution discovered by Gaston Ramon 1923 to detoxify toxin preserving immunogenicity. Mechanism involves cross linking lysine residues via hydroxymethyl intermediates forming methylene bridges disrupting catalytic site while preserving conformational epitopes recognized by neutralizing antibodies. Incubation with 0.2-0.6 percent formalin at 37°C pH 6-7 for several weeks converts toxin to toxoid losing toxicity but retaining ability to induce antitoxin antibodies that bind toxin preventing attachment to receptors. Verification by lack of toxicity in guinea pig challenge assay and absence of residual free formaldehyde. Toxoid adsorbed to aluminum salts generates long lasting IgG antitoxin, cornerstone of diphtheria tetanus control since 1920s, eliminating former leading causes childhood mortality.

Ref: Rappuoli Nat Rev Microbiol Toxoid formalin; Glenny 1920s Toxoid; WHO Toxoid production formalin.

View Details

Vaccine

Inactivated vaccines usually require:

Inactivated vaccines usually require multiple doses and periodic boosters to achieve and sustain protective immunity because non replicating antigen provides transient immune stimulation. Initial dose primes naive B cells in draining lymph nodes producing low affinity IgM and modest IgG, small memory pool, titer often below correlate of protection threshold. Second dose administered 4-8 weeks later triggers anamnestic response with larger germinal center reaction, extensive somatic hypermutation in dark zone mediated by activation induced cytidine deaminase, affinity maturation, isotype class switching to IgG1 and IgG3 high neutralizing activity, expansion of long lived plasma cells homing bone marrow. Third dose further raises affinity. However antibody wanes over months to years because antigen depot cleared quickly unlike replicating live vaccine persisting weeks. Therefore boosters at 12-18 months and school entry maintain immunity. Examples hepatitis B series three doses at 0,1,6 months achieving seroprotection 95 percent, IPV three doses plus booster, DTP five doses. Reliance on multiple doses impacts compliance, coverage, programmatic cost, requiring tracking immunization records, reminder systems. Adjuvants reduce number but still need repeat exposures; oral live vaccines require single dose.

Ref: Plotkin Why inactivated needs multiple doses; WHO Immunization schedule; Amanna Duration.

View Details

Vaccine

Inactivated vaccines differ from live vaccines because they:

Inactivated vaccines fundamentally differ from live attenuated vaccines because they cannot replicate within host tissues. Inactivation achieved by chemical agents formaldehyde crosslinking proteins, beta-propiolactone alkylating nucleic acids, heat denaturation destroying polymerase enzymes, while preserving epitopes for antibody recognition. Because genome destroyed, no progeny virions produced, infection cycle aborted, inability to cause disease even if host immunocompromised. Immunologically absence of cytosolic replication reduces engagement of RIG-I, MDA5 cytosolic sensors sensing replicating RNA, resulting in weaker type I interferon and CD8 T cell response primarily relying on exogenous antigen uptake presented via MHC II to CD4 helpers producing mainly humoral immunity. Duration shorter necessitating adjuvants like aluminum hydroxide forming depot, enhancing uptake by dendritic cells, activating NLRP3 inflammasome IL-1 beta release. Inactivated vaccines include IPV, HAV, influenza split, rabies. They exhibit increased safety, no shedding, no reversion, but require higher doses often multiple injections to achieve protective titers. Distinction impacts storage, contraindications and schedule design with more boosters required to maintain herd immunity threshold.

Ref: Baxter J Clin Virol 2007 Inactivated cannot replicate; Plotkin Inactivated vs Live difference; CDC.

View Details

Vaccine

Which vaccine is administered orally?

Oral polio vaccine OPV is classical example administered via oral route as drops rather than injection. Formulated by Albert Sabin in 1957 containing live attenuated poliovirus types 1,2,3 propagated in primary monkey kidney cells, stabilized with MgCl2, sucrose, buffered. Oral delivery mimics natural fecal oral transmission of wild poliovirus. Attenuated virus replicates in M cells of Peyer's patches, gut associated lymphoid tissue generating strong intestinal secretory IgA preventing colonization and transmission, plus systemic IgG and intestinal CD4 T cells. Advantages include easy administration by volunteers without training, low cost, non sterile technique, secondary spread to contacts via fecal shedding increasing community immunity, cold chain still required but thermostable formulations being developed. OPV contributed to near eradication reducing polio cases 99 percent since 1988. However rare reversion of attenuating mutations in 5'UTR and VP1 capsid leads to vaccine derived poliovirus VDPV causing paralysis and circulating cVDPV outbreaks, prompting switch to inactivated IPV in many countries. Other oral vaccines include rotavirus pentavalent, cholera WC-rBS, typhoid Ty21a illustrating mucosal immunity advantages.

Ref: WHO OPV oral vaccine; Sabin J Exp Med 1957; Plotkin Polio oral route.

View Details

Vaccine

Live attenuated vaccines are contraindicated in:

Live attenuated vaccines contraindicated in immunocompromised individuals because control of limited replication depends on intact innate and adaptive immune compartments. Immunocompromise includes congenital severe combined immunodeficiency affecting T cells, chronic granulomatous disease phagocyte defect, HIV with CD4 count below 200 cells per microliter in adults or below 15 percent in children, chemotherapy causing neutropenia, high dose systemic corticosteroids more than 2 mg per kg prednisone for 2 weeks, biologic agents anti TNF monoclonal antibodies, organ transplant recipients receiving calcineurin inhibitors tacrolimus suppressing T cell activation. In such hosts even attenuated strains can cause uncontrolled replication resulting in disseminated BCGitis with hepatosplenic granulomas after BCG, progressive vaccinia with necrotic lesions after smallpox vaccine, vaccine associated paralytic polio due to persistent poliovirus excretion and reversion, severe varicella from Oka vaccine. Pregnancy also contraindication due to potential fetal infection although risk theoretical. Therefore guidelines WHO advise use of inactivated, toxoid, subunit, conjugate, mRNA vaccines in immunocompromised which cannot replicate. Screening via HIV testing, medication history before live vaccine essential to avoid iatrogenic infection.

Ref: CDC Contraindications immunocompromised live; Plotkin Immunocompromised host; Red Book AAP.

View Details

Vaccine

A major advantage of live attenuated vaccines is:

Major advantage of live attenuated vaccines lies in induction of strong, durable, broad immunity closely mimicking natural infection without causing disease in immunocompetent hosts. Limited replication provides continuous antigen synthesis over days to weeks prolonging immune exposure far beyond bolus injection of killed antigen, sustaining germinal center reactions, affinity maturation and generation of long lived plasma cells producing high affinity IgG persisting decades and memory B cells. Activation of cytosolic innate sensors RIG-I, MDA5, STING by replicating nucleic acids induces robust type I interferon, IL-12, potent CD8 cytotoxic T cell differentiation producing IFN gamma and perforin granzyme killing infected cells, important for viral clearance. Mucosal live vaccines like OPV and rotavirus elicit secretory IgA at portal entry preventing colonization transmission. Single dose often sufficient, sometimes lifelong, reducing programmatic complexity, compliance issues and costs compared to multiple booster schedules required for inactivated vaccines. Examples measles vaccine protection documented more than 20 years, yellow fever 30 years. However safety concern in immunocompromised due to potential progressive infection requires screening contraindications, outweighing advantage in vulnerable populations.

Ref: Amanna Nature Medicine 2007 Live vaccine long immunity; Plotkin Advantage robust; Pulendran.

View Details

Vaccine

Live attenuated vaccines are weakened by:

Live attenuated vaccines are weakened by serial passaging in non natural host cell cultures, tissues or under suboptimal temperature forcing accumulation of adaptive mutations and deletion of virulence genes. Method pioneered by Louis Pasteur for anthrax and rabies via passage in animals. For viral vaccines, poliovirus Sabin strains passaged in monkey kidney and mouse spinal cord selecting neurovirulence attenuating mutations in 5'UTR internal ribosome entry site reducing replication in neurons while retaining replication in gut. Measles Edmonston strain passaged in primary human kidney cells, chick embryo fibroblasts adaptation to avian receptors reducing human pathogenicity. BCG created by 230 serial passages of Mycobacterium bovis on potato bile glycerin medium 1908-1921 resulting loss of RD1 region encoding ESX-1 secretion system essential for virulence. Alternative modern strategies include cold adaptation growing influenza at 25°C selecting viruses replicating in cooler upper respiratory tract not warm lower lung, generation of reassortants, or reverse genetics deleting virulence genes like HSV ICP34.5. Attenuated microbe replicates limitedly presenting native antigens via both MHC pathways, inducing strong cellular immunity. Reversion monitored by sequencing.

Ref: Pasteur attenuation principle; Plotkin live vaccine passage; WHO Live attenuated methods.

View Details

Vaccine

Which of the following is NOT a whole-microbe vaccine?

Whole microbe vaccines contain complete intact microorganism either living attenuated with reduced virulence but replicating or killed inactivated retaining structural integrity but replication abolished. Examples live BCG, measles MMR, oral polio, live influenza cold adapted; killed whole cell pertussis, inactivated polio IPV, rabies, influenza whole virion. Subunit vaccines diverge by containing only specific antigenic components rather than entire organism, thereby not considered whole microbe. They include purified capsular polysaccharides, polysaccharide-protein conjugates, acellular pertussis proteins pertussis toxin, filamentous hemagglutinin, pertactin, recombinant hepatitis B surface antigen self-assembling virus like particles produced in yeast, split influenza HA NA subunits after detergent disruption, recombinant spike protein nanoparticles. Subunit vaccines offer improved safety unable to revert to virulence, lower reactogenicity due to removal of toxic components like lipopolysaccharide, defined composition permitting standardization, but often less immunogenic requiring adjuvants and booster schedules to compensate for lack of innate stimuli provided by whole microbe pathogen associated molecular patterns. Thus subunit is distinct category, excluded from whole microbe classification.

Ref: Plotkin Vaccines Chapter Classification whole microbe vs subunit; WHO Vaccine types.

View Details

Vaccine

A vaccine is best defined as:

A vaccine is best defined as immuno-biological product containing all or part of microorganism or its products, synthetic or recombinant antigens, mRNA or viral vector engineered to express antigen, formulated to induce active acquired protective immunity against specific infectious disease or tumor without causing disease itself. It comprises immunogenic principle plus diluents, stabilizers such as sucrose, surfactants, buffers maintaining pH, preservatives like 2-phenoxyethanol preventing bacterial contamination in multidose vials, and sometimes adjuvants aluminum salts, MF59, AS01 enhancing innate activation. Quality attributes include potency measured by in vitro ELISA or in vivo challenge, sterility, purity, safety, absence of extraneous agents. Unlike antibiotics that directly kill bacteria by targeting cell wall synthesis, antibiotics are therapeutic chemotherapeutics, vaccines prophylactic training host defense. Mechanism involves antigen presentation, germinal center formation, affinity maturation, memory generation measurable as neutralizing antibody titer correlate of protection. Vaccines classified prophylactic preventing infection, therapeutic treating existing disease like therapeutic cancer vaccines targeting neoantigens. Definition emphasizes immunity induction rather than direct pathogen killing, distinguishing immunobiological from chemical drug or metabolic inhibitor categories.

Ref: WHO Vaccine definition; Plotkin Vaccines 7th ed Ch 1 immunobiological; CDC NIP.

View Details